Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This on-demand content has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed, and prescribing information can be found at the bottom of this page. Lilly is a registered trademark of Eli Lilly and Company. © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine)Humalog® (insulin lispro)Lyumjev® (insulin lispro) (Please note: Lyumjev is not available in the ROI), Trulicity® (dulaglutide). For more information about Lilly products please visit www.lillydiabetes.co.uk (UK only).

fast forward:

Improved treatments, technology and teamwork

The 21st Abracadabra Diabetes Nursing Conference was held in 2021 as a series of virtual webcasts over three separate days. The conference was well attended and included respected speakers who presented a range of highly informative content about matters concerning diabetes care. These webcasts have now been developed into a series of on-demand videos that will allow healthcare professionals to access this valuable educational content at their own convenience.

Presented by a panel of experts the range of topics includes: 

  • Diabetes communication in the 21st century – A critical examination of the effect of language on people with diabetes and providing advice on how to improve communication in healthcare
  • Diabetic kidney disease: challenges and opportunities – A guide to the clinical management of the person identified as having kidney disease in the context of diabetes
  • The challenges of post-prandial hyperglycaemia: strategies and insights – How post-prandial glucose control can be improved in a therapeutic context to engage and empower people living with diabetes
  • Pregnancy planning, gestational diabetes and post-pregnancy support: A perspective from the clinic – An experienced nurses’ perspective on the control of diabetes during pregnancy, and how diabetes care can be optimised during this time

This promotional on-demand content has been developed, organised and funded by Lilly in conjunction with the
Abracadabra Programme Planning Committee

For Prescribing Information and Adverse Event reporting please scroll to the bottom of the page

Broadcast on 6th May 2021

Play Video

100 years of insulin - from Banting to bolus

Professor Partha Kar, Consultant Diabetologist, Portsmouth
Dr Kunal Gulati, Senior Medical Lead, Lilly Diabetes

Play Video

Maximising the Benefits from Recent Advances in Diabetes Technology

Dr Peter Hammond, Consultant Endocrinologist, Harrogate and District NHS Foundation

Play Video

Diabetes Communication in the 21st Centrury

Dr Dorothy Frizelle, Constultant Clinical Health Psychologist, Mid Yorkshire Hosptials NHS Trust

Broadcast on 11th May 2021

Play Video

Diabetic Kidney Disease: Challenges and Oppurtunities

Dr Andrew Frankel, Consultant Nephrologist, Imperial College Healthcare NHS Trust

Prescribing information: Trulicity® (dulaglutide).
Play Video

Managing cardiovascular risk in adults with type 2 diabetes and the multifactorial role of Trulicity® (dulaglutide)?

Dr Yassir Javaid, MA (Cantab), FRCGP, FRCP, PGDip Cardiology, GPwSI Cardiology & RCGP Clinical Adviser, Cardiovascular Lead, East Midlands Clinical Network

Prescribing information: Trulicity® (dulaglutide).
Play Video

Too high, too low: the consequences of suboptimal glycaemic control

Dr Kevin Fernando, GP, North Berwick, near Edinburgh

Broadcast on 14th May 2021

Play Video

Pregnancy planning, gestational diabetes and post-pregnancy support – A perspective from the clinic

Su Down, Nurse Consultant Diabetes, Somerset Foundation Trust

Play Video

The challenges of post-prandial hyperglycaemia: strategies and insights

Dr Emma Wilmot, Consultant Diabetologist, University Hospitals Derby; Assistant Professor, University of Nottingham

Prescribing information:  Lyumjev® (insulin lispro)
Play Video

Why is being a Diabetes Specialist Nurse like being a person with diabetes?

Dr Mark Davies, Consultant Clinical Psychologist, Belfast Health and Social Care Trust

Play Video

2010 to 2020, Standing on the Shoulders of Giants

Dr Matthew Murphy, South Infirmary Victoria University Hospital, Cork, Ireland

Prescribing information: Trulicity® (dulaglutide).
Play Video

A Guide to Caring for Feet in People with Diabetes

Mr David Watterson, Podiatry Clinical Manager of CHO Area 2, Galway

Play Video

Before, during and after pregnancy with pre-existing diabetes: A Registered Advanced Midwife Practitioner (RAMP) Diabetes perspective

Yvonne Moloney, Registered Advanced Midwife Practitioner Diabetes, University of Limerick Hospitals Group

This on-demand content has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed, and prescribing information can be found at the bottom of this page. Lilly is a registered trademark of Eli Lilly and Company. © 2021 Eli Lilly and Company. All rights reserved.

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine)Humalog® (insulin lispro)Lyumjev® (insulin lispro) (Please note: Lyumjev is not available in the ROI), Trulicity® (dulaglutide). For more information about Lilly products please visit www.lillydiabetes.co.uk (UK only).

Adverse events and product complaints should be reported. Reporting forms and further information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store (UK) or www.hpra.ie (ROI). Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on +44 (0) 1256 315000 or Lilly Ireland on +353 (0)1 664 0446 (ROI).

PP-LD-GB-1255 | June 2021

This content is password protected. To view it please enter your password below:

This webcast was developed by the Primary Care Network faculty in conjunction with OmniaMed Communications. The sponsoring companies have provided sponsorship to Omniamed Communications to support the costs of running the webcast, the resource area on Diabetesonthenet and supporting collateral. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content.

Delivery of Diabetes Care in the Primary Care Network

The changing shape of clinical practice

Originally broadcast on
21 April 2021

Speakers

Sarah N Ali

Sarah N Ali

Consultant Diabetologist, Royal Free London NHS Foundation Trust

Sarah Alicea

Sarah Alicea

Diabetes Specialist Dietitian, University Hospitals Dorset NHS Foundation Trust

Lorraine Avery (3)

Lorraine Avery

Community Diabetes Specialist Nurse, Solent NHS Trust

Hannah Beba

Hannah Beba

Senior Clinical Pharmacist for Diabetes and Endocrinology, County Durham and Darlington NHS Foundation Trust

Naresh Kanumilli

Naresh Kanumilli

Community Diabetes Consultant, Manchester University NHS Foundation Trust

Nicola-Milne_1.jpg

Nicola Milne

Community DSN, Manchester University NHS Foundation Trust

Sponsors

astrazeneca-logo-19-1 (1)
boehringer ingelheim
lilly-logo-19-1
napp-logo-19-1
novo-nordisk-logo-19-1
sanofi-logo-19-1

This webcast was developed by the Primary Care Network faculty in conjunction with OmniaMed Communications. The sponsoring companies have provided sponsorship to Omniamed Communications to support the costs of running the webcast, the resource area on Diabetesonthenet and supporting collateral. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content.

A focus on obesity management in the UK

Obesity is a serious chronic condition associated with great physical and psychological impact on the quality of life of those who live with it – as well as placing pressure on the finances and resources of the NHS. Yet healthcare professionals have limited options for helping patients to manage the condition: until very recently, there have been limited pharmacological treatment options available apart from Orlistat.

These videos provide an update on the pharmacotherapy for obesity available to healthcare professionals in the NHS: Saxenda® (liraglutide 3mg), the NICE Single Technology Appraisal (STA) for Saxenda®, which of your patients may be suitable for this therapy, and how the guidance could affect the way you treat your patients with obesity.

This promotional resource is organised and funded by Novo Nordisk.
The information presented is intended for UK-based healthcare professionals.

Changing Paradigms: A focus on
obesity management in the UK

The landscape of obesity management - What do we know?

Prof John Wass

Play Video

Saxenda® (liraglutide 3mg) and the current evidence

Dr Carel Le Roux

Play Video

Saxenda® NICE Single Technology Appraisal (STA)
and what you need to know

Dr Abd Tahrani (Chair)

Play Video

Prof Carel Le Roux

Consultant in Metabolic Medicine, King's College Hospital, London

Professor Carel Le Roux graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. He obtained his PhD from Imperial College London where he later took up a faculty position. He moved to University College Dublin for the Chair in Experimental Pathology and he is now a Director of the Metabolic Medicine Group. He currently coordinates an Innovative Medicine Initiative project on obesity. He previously received a President of Ireland Young Researcher Award, Irish Research Council Laurate Award, Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.

Dr Abd Tahrani (Chair)

Senior Lecturer in Endocrinology and Obesity Medicine, University of Birmingham; Consultant Endocrinologist and Bariatric Physician, University Hospitals Birmingham NHS Foundation Trust

Abd Tahrani is a Senior Lecturer in Metabolic Endocrinology and Obesity Medicine at the University of Birmingham (UoB). Abd is also an Honorary Consultant in Endocrinology, Diabetes & Weight Management, and the lead for weight management research and diabetic neuropathy services at the University Hospitals Birmingham NHS Foundation Trust. He is the lead for translational research in the Centre of Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners.

Abd received several awards including NIHR research training fellowship (2008), NIHR Clinician Scientist (2012), the American Academy of Sleep Medicine Young investigator award in OSA research (2013), SCOPE National & International Fellowships from the World Obesity Federation in (2014 & 2020). Abd’s research themes are: 1) the metabolic consequences of sleep-related disorders, 2) obesity management & health care delivery, 3) diabetes-related neuropathy. 

Abd has published over 150 peer reviewed articles and delivered more than 100 invited talks in the leading conferences globally.  Abd is a trustee of ASO (UK), a panel member of the NIHR RfPB, and the British Sleep Society Research Committee. Abd is also and an Expert advisor to NICE and a member of the strategic council of the Obesity All Party Parliamentary Group (Obesity APPG). He is the co-Chair of the Clinical practice and Obesity Management Committee of ASO (UK) and a member of the Obesity Policy Engagement Network (OPEN) UK. He is a regular peer reviewer to the leading journals and research funding organisations. Abd is an associate editor for the European Journal of Endocrinology and the Diabetes Section Editor for BMC Endocrine Disorders.

Prof John Wass

Professor of Endocrinology, University of Oxford

John Wass is the Professor of Endocrinology at Oxford University and was Head of the Department of Endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital Oxford, UK until 2012.

His research interests include all pituitary tumours, especially acromegaly, adrenal disease, angiogenesis in endocrinology, and the genetics of osteoporosis and thyroid disease.

Since 1975 he has published over 385 articles in scientific journals and as well as written many reviews and chapters in textbooks including the Oxford Textbook of Medicine and DeGroot’s Textbook of Endocrinology.  He has also edited a number of different textbooks including the Oxford Textbook of Endocrinology, Clinical Endocrine Oncology and the Oxford Handbook of Endocrinology (3 editions).  He was President of the European Federation of Endocrine Societies from 2001-2003 and was Chairman of the Society for Endocrinology (2006-2009.  He has also served as President of the Pituitary Society.

He has won a number of prizes and given named lectures including the Jubilee Prize of the Society for Endocrinology.  He was recently in June last year awarded the Distinguished Physician of the Year Award by the American Endocrine Society; the first non American to ever receive this award.

Amongst his charitable activities, he is Patron of the St. Pauls Way School (with Professor Brian Cox) and he founded the Pituitary Foundation.

He was Academic Vice President of the Royal College of Physicians in London, from August 2012 until August 2015.

He chaired the Royal College of Physicians Working Party ‘Action on Obesity: Comprehensive Care for All’ published in January 2013, and has been involved improving services for patients with obesity.

Recently he presented the acclaimed documentary ‘The Fantastical World of Hormones’ on BBC4.

Prescribing information for Saxenda® (liraglutide) can be accessed by clicking here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.
This promotional resource is organised and funded by Novo Nordisk.
The information presented is intended for UK-based healthcare professionals.

Job code: UK21SX00082 | Date of preparation: March 2021

Sponsored by Abbott

Speaker Biographies

Su Down

Diabetes Nurse Consultant

Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset. Nationally, she is the Editor in Chief of the Journal of Diabetes Nursing and joint Vice Chair of the PCDS (Primary Care Diabetes Society). Former national roles have included being a TREND associate, board member of FIT (Forum for Injection Technique) and committee member of the Health Care Professionals Council of Diabetes UK.

The constant challenge of ensuring that an equitable service is delivered to the ever-growing population of Somerset is one that Su finds highly rewarding. Furthermore, she has relished being able to have an influence on both national and international projects.

Dr Emma Wilmot

MB ChB BSc (hons) PhD FRCP

Dr Emma Wilmot is a Consultant Diabetologist at University Hospitals of Derby and Burton NHS Foundation Trust. In 2018 she was appointed as an Honorary (consultant) Assistant Professor at the University of Nottingham. Her specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.

Dr Wilmot is founder of the ABCD Diabetes Technology Network UK and an elected Association of British Clinical Diabetologists (ABCD) committee member and DAFNE structured education executive board member. She is a member of the National Diabetes Audit Insulin Pump Expert Reference Group and has also been involved in the #languagematters movement. She is the principal investigator on several diabetes research trials.

Video

Diabetes perspectives: An introduction to Flash Glucose Monitoring

This comprehensive on demand video provides an excellent introduction to flash glucose monitoring in primary care.
The video includes:

This video was originally broadcast on 7 December 2020. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.

In association with

Time in range
Is this the new gold standard?

Exploring the role of technology and modern insulins for improving glycaemic control in diabetes

*CGM-based targets for adults with type 1 and type 2 diabetes who are not pregnant, not older, or at risk
†Readings >13.9 mmol/L are also included
‡Readings <3.0 mmol/L are also included
This visual was adapted from Battelino T et al (2019) Diabetes Care 42:1593–603

This promotional resource is organised and funded by Novo Nordisk and Abbott.
Marketing and organisational support has been provided by OmniaMed Communications.
The information presented is intended for UK-based healthcare professionals.
Adverse event reporting information and prescribing Information will be available on this website.

Time in range
Is this the new gold standard?

Developments in modern insulins and improvements in flash glucose monitoring technology in diabetes have improved the time that glucose levels remain within target range.

This on demand video features a clinical discussion hosted by Dr Fiona Campbell,  Consultant Paediatrician and Diabetologist and Prof Ramzi Ajjan, Professor of Metabolic Medicine both based at The Leeds Teaching Hospitals NHS Trust. They will explore how technology can facilitate the use of modern insulins to improve glycaemic control and discuss how devices and medicine can be combined to improve the quality of life for individuals with diabetes.

Speakers

Dr Fiona Campbell

Consultant Paediatrician and Diabetologist,
The Leeds Teaching Hospitals NHS Trust
Fiona Campbell has been a Consultant in Paediatric Diabetes for 24 years. She is Associate Medical Director at Leeds Teaching Hospitals NHS Trust, responsible for Children and Young People’s Services, and Trust-wide Clinical Lead for Transition. Clinically, Dr Campbell leads a large diabetes service at Leeds Children’s Hospital, Leeds, caring for patients aged between 0 and 20 years. She has been Chair of the National Children and Young Peoples Diabetes Network in England and Wales, and a member of the National Paediatric Diabetes Audit Project Board for the last 7 years. Internationally, Dr Campbell is a member of the International Society for Paediatric and Adolescent Diabetes and is currently serving her second 3-year term of office on the Council of Healthcare Professionals at Diabetes UK, ensuring that the interests of children and young people living with diabetes are addressed. Most recently Dr Campbell has taken on the role of Diabetes Officer at British Society of Paediatric Endocrinology and Diabetes.

Prof Ramzi Ajjan

Professor of Metabolic Medicine,
The Leeds Teaching Hospitals NHS Trust

Ramzi Ajjan is Professor of Metabolic Medicine and Honorary Consultant in Diabetes and Endocrinology at Leeds University and Leeds Teaching Hospitals Trust. He obtained his PhD from the University of Sheffield and completed his clinical training in Diabetes and Endocrinology at Leeds Teaching Hospitals. He runs a programme of basic, translational and clinical research studies with the collective aim of reducing vascular complications and improving quality of life in individuals with diabetes. He has authored over 150 publications including original articles, reviews and book chapters. His clinical practice concentrates on young adults with diabetes and older individuals at high risk of vascular disease.
He is local research and development lead for Diabetes/Endocrinology and regional clinical research network co-lead for diabetes, endocrine and metabolic conditions. He is deputy Chair of the Clinical Study Group 2 at Diabetes UK, Associate Editor of Diabetes and Vascular Disease Research and member of the editorial board of International Journal of Molecular Sciences.

Video

Play Video

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

Play Video

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

Play Video
Prescribing information for Fiasp® (insulin aspart) can be found here.
Prescribing information for Tresiba® (insulin degludec) can be found here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

Job code: UK21DI00015; ADC-31344 v1.0. Date of preparation: February 2021

Abracadabra

2020 Virtual Conference

Abracadabra

In association with the

Back to the future

Combining two decades of nurse education with latest evidence and therapies to deliver individualised care

The 20th Abracadabra Diabetes Nursing Conference in 2020 was held as a series of virtual webcasts over three separate days. The conference was well received and provided very informative content.

Now, the webcasts have been developed into a series of on demand videos to allow healthcare professionals to access this excellent video content at their convenience.

Presented by a panel of expert speakers a range of topics are covered including:

  • Diagnosing the right type of diabetes
  • GLP-1 receptor agonists: Turning research into clinical practice
  • Variation of care in diabetes and getting it right first time
  • Post-prandial excursions: Overcoming the barrier to time-in-range
These promotional virtual conferences have been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee
Play Video
2020: The Year of the Nurse

Jane Diggle, Specialist Practitioner Practice Nurse, South Kirkby

Jane Diggle a Specialist Practitioner Practice Nurse from South Kirby in West Yorkshire continues the theme of the ‘Year of the Nurse’ by examining how the role of nurses in diabetes has changed over time. The presentation then looks forward at the key challenges and changes facing the nursing profession.

Play Video
Diabetes and multi-morbidities

Dr Kevin FernandoGP, North Berwick, near Edinburgh

Dr Kevin Fernando gives an overview of major comorbidities in type 2 diabetes. He examines the best ways to assess risk using calculators and other tools and provides best practice advice about how to care for and manage older and frail individuals based upon long term clinical trial evidence.

Play Video
Diagnosing the right type of diabetes

Dr Sarah DaviesGP with Special Interest in Diabetes, Cardiff

In this video Dr Sarah Davies explains the different diabetes types and their key features. She examines the best approach to more complex cases and provides suggestions about what to do when the diagnosis is unclear. The last section of the video provides information about how to understand the rarer forms of diabetes.

Play Video
‘From clinic with love’: Engaging young people with diabetes

Jo DaltonDiabetes Specialist Nurse – Transition, Poole Young People’s Diabetes Service

Jo Dalton a Diabetes Specialist Nurse in Poole, West Dorset explains her groundbreaking method to motivate young people with diabetes. Using a case study based on the Poole Young People’s Diabetes Service she describes the system and how the concept could be expanded to additional patient groups and other chronic conditions.
Play Video
Future-proofing diabetes nursing: 21st Century and beyond

Nicola MilneCommunity Diabetes Specialist Nurse, Manchester

With 2020 being the ‘Year of the Nurse’ Nicola Milne a Community Diabetes Specialist Nurse in Manchester examines what the future could hold for nursing recruitment, competencies and skills. The video considers how nurses can deliver innovation into their practice and provides advice on nurses looking after their own health and well-being.

Play Video
GLP-1 receptor agonists: Turning research into clinical practice

Prof Mike CummingsProfessor of Diabetes and Endocrinology at Portsmouth NHS Trust

Dr Sumer AdityaConsultant Physician in Diabetes and Endocrinology, Aintree

In this keynote video Professor Mike Cummings and Dr Sumer Aditya examine GLP-1 receptor agonists. They provide a comprehensive examination of the guidelines. And then look at how GLP-1 receptor agonists fit into clinical practice with insights into practical use and safety. Finally, they give an update on the GLP-1 receptor agonist cardiovascular safety trials.

Contains promotional information

Play Video
New ways of working: A crisis or an opportunity?

Dr Heather BellGP, Greenisland, Northern Ireland

Remote consultation is becoming a reality for many. Dr Heather Bell examines how to adapt to new ways of working and gives advice on patient prioritisation and risk stratification. The video concludes by providing practical tips on virtual consultation and the most effective use of Real-World Data.

Play Video
Post-prandial excursions: Overcoming the barrier to optimal time-in-range

Dr Emma WilmotConsultant Diabetologist, University Hospitals Derby; Assistant Professor, University of Nottingham

Dr Emma Wilmott examines how post-prandial glucose contributes to overall blood glucose control. She looks at how to optimise patient insulin, including a discussion about carbohydrate ratios and insulin correction factors. Finally, Dr Wilmott examines the benefits of new fast-acting insulins.

Contains promotional information

Play Video
Variation of care in diabetes – and Getting It Right First Time

Professor Partha KarConsultant Diabetologist, Portsmouth

Professor Partha Kar provides a unique insight into the ‘Getting it Right First Time Report’. He provides a status update for the report, looks at what we know so far about variations in hospital-based diabetes care and provides a plan for the next steps and implementation of the report findings.

Play Video
Virtual clinics: Is necessity the mother of invention?

Su DownDiabetes Nurse Consultant, Somerset

With COVID-19 being a part of everyday life at the current-time Su Down a Diabetes Nurse Consultant in Somerset examines how COVID-19 has changed the concept of a clinic. By looking at the challenges of new communication platforms, Su Down provides her personal experience of running virtual clinics and poses the question, can virtual working become part of our ‘normal’ practice?

Please click here for prescribing information for Trulicity® (dulaglutide), Humalog® (insulin lispro), Abasaglar® (insulin glargine) and Lyumjev® (insulin lispro) (Lyumjev is not available in the ROI).

For more information about Lilly products please visit www.lillydiabetes.co.uk (UK only; this link is not available in the ROI)

Adverse events and product complaints should be reported. Reporting forms and further information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store (UK) or www.hpra.ie (ROI). Adverse events and product complaints should also be reported to Lilly: please call Lilly on +44 (0) 1256 315000 (UK) or +353 (0)1 664 0446 (ROI).

These promotional virtual conferences have been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee.
Lilly is a registered trademark of Eli Lilly and Company
© 2020 Eli Lilly and Company. All rights reserved

PP-LD-GB-1004 Nov 2020

An hour-long interactive webinar (now on-demand)

Webinar 1

Risk stratification in Primary Care

Webinar 2

Prescribing Guidance in Primary Care

This virtual broadcast series has been funded by Novo Nordisk. Novo Nordisk has had no editorial input into, or control over, the content of the webinar. PCDS is responsible for the content of the webinar and the selection of speakers.

In these challenging times, healthcare professionals (HCPs) caring for people with diabetes need to ensure that essential care continues, following most recent prescribing guidance. In addition, with the gradual return to regular clinics, careful thought is required as to who should be prioritised for call back and why.

The first broadcast chaired by Claire Hambling a GP from Norfolk and Chair of the Primary Care Diabetes Society, examined, from a primary care perspective, the latest guidance regarding risk stratification of people with diabetes and how this might be adopted in practice. 

In the second broadcast chaired by David Millar-Jones, a GP from Cwmbran and PCDS Committee member, there was a focus on prescribing guidance and the importance of following latest advice in order to deliver optimum long-term outcomes for patients, whilst taking into account potential co-morbidities associated with diabetes.

Webinar 1

Play Video

Risk stratification in Primary Care

This video was originally broadcast on 1 October 2020. Please note that the speaker is not able to answer questions from attendees watching the video on-demand.

Resources

Play Video

Question Time debate

How to prioritise primary care diabetes services during and post COVID-19 pandemic

At a glance factsheet: Sources of information and education for people with diabetes to support remote consulting

2020/21 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF)

Webinar 2

Play Video

Prescribing Guidance in Primary Care​

This video was originally broadcast on 8 October 2020. Please note that the speaker is not able to answer questions from attendees watching the video on-demand.

Resources

Play Video

Question Time debate

PCDS Question Time: Prescribing guidance in primary care question and answer summary

Speakers

Sarah Davies

GP Partner, Cardiff

Sarah Davies is a GP Partner in Cardiff with a special interest in diabetes, and is passionate about general practice, particularly great quality diabetes care in the primary care setting.

She qualified at the University of Wales College of Medicine in 2003 and initially trained as a physician with a view to becoming an endocrinologist, before making the excellent move into general practice. She has never looked back! Sarah has continued to develop her interest in diabetes, and presents regularly on the subject to colleagues at local and national meetings. This allows her to indulge her passion for public speaking, share her enthusiasm for the subject and promote her aim that all healthcare professionals in primary care should have access to appropriately targeted diabetes education.

She is the Clinical Director for Diabetes in Primary Care for Cardiff and Vale UHB, a Diabetes UK Clinical Champion and a presenter for NB Medical Education’s Hot Topics, leading their diabetes course.

Jane Diggle

Specialist Practitioner Practice Nurse, South Kirkby

Jane qualified with a BSc (Hons) in Nursing in 1990 (Leeds) and has been a nurse within the same practice for over 20 years. Whilst she retains a generalist role, her special interest is in diabetes for which she is clinical lead within her practice. She is an independent prescriber and has gained MSc modules in Insulin Management and New & Advanced Therapies from Leicester University.

She was appointed Co-Vice Chair of the Primary Care Diabetes Society in 2016 and has been part of the committee since 2010 (www.pcdsociety.org) . She is Associate Editor-in-Chief for Diabetes and Primary Care Journal, regularly publishes articles on practical aspects of diabetes care and was instrumental in developing and writing Six Steps to Insulin Safety (a free e-learning module launched in 2016 and available at www.cpd.diabetesonthenet.com). Jane regularly speaks at national conferences on aspects of diabetes management. She is co-founder of Injection Technique Matters.

Su Down

Diabetes Nurse Consultant, Somerset

Su has specialised in diabetes for 25 years and since 2005 has held the position of Diabetes Nurse Consultant in Somerset. She has played a key role in leading the service through a complete redesign and implementing a community-based team of diabetes specialist nurses and specialist dietitians.

Su’s particular interests are in elderly care, end-of-life care, insulin safety, injection technique, hypoglycaemia and pregnancy care. In her role as Clinical Lead for the intermediate service, she is responsible for the clinical supervision of the nursing team and the service is commissioned to deliver healthcare professional education to primary care, to the community nursing service and to care homes. The service also delivers group education to those with type 1 and type 2 diabetes.

Nationally, Su sits on the board of the Forum for Injection Technique and has developed diabetes modules for the social care sector in conjunction with Skills for Care. She is also on an international board looking to explore the challenges in early conversations between clinicians and people with diabetes. She presented this work at the recent EASD conference. She has had work published on topics including service redesign, the future role of specialist nurses, innovative commissioning, injection technique and hypoglycaemia unawareness.

Kevin Fernando

GP Partner, North Berwick

Kevin is a part-time GP Partner & GP Educational Supervisor working at the coalface in North Berwick Health Centre, near Edinburgh. Kevin is also Scottish lead of the Primary Care Diabetes Society and an observer member of the Primary Care Cardiovascular Society. Other roles include RCGP Clinical Advisor for Diabetes & Multimorbidity and also Education Director for GPNotebook Education.

Kevin graduated from the University of Edinburgh in 2000 and holds both MRCGP and MRCP(UK) qualifications and has completed a Master’s degree in diabetes which he passed with distinction.

Kevin has been elected to Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh and also the Academy of Medical Educators for his work in diabetes and medical education.

Clare Hambling (Chair)

GP, West Norfolk

Clare Hambling is a GP with a passionate interest in diabetes. She is Chair of the West Norfolk Diabetes Network and a member of the programme board for the East Anglia Diabetes Retinal Screening Service. She is an active contributor to the Eastern Academic Health Science Network’s Diabetes Projects Group, providing a primary care perspective on the development of an integrated “hypo pathway” for the whole of the East of England.

Working in West Norfolk, Clare has developed a particular interest in diabetes management in older people. She has recently received a Quality Improvement Award from the East Anglia Faculty of the Royal College of General Practitioners for a locality-wide project aimed at reducing overtreatment and hypoglycaemia risk among older people with type 2 diabetes.

Clare also has an interest in education and evidenced-based practice. She is a Senior GP Tutor for the University of Cambridge and a Clinical Adviser for the to the Royal College of General Practitioners.

Patrick Holmes

GP, Darlington

Patrick Holmes has been a full-time GP/Partner in the same medical practice in the town of Darlington, in the North of England, for the past 19 years. In addition to this, he works part-time as a GPwSI in Diabetes visiting a number of medical practices in the Derwentside area of County Durham. He has also been the local CCG diabetes lead for the past 12 years.

Stephen Lawrence

Primary Care Clinical Lead, Chatham

Stephen Lawrence is a Primary Care Clinical Lead in Chatham. He graduated from Leeds University Medical School in 1987. His interest in metabolic medicine was awakened when he completed a BSc (Hons) degree in Chemical Pathology during his intercalated year. He has previously worked as a Medical Advisor for Prisons at the Department of Health, where he participated in an award-winning prison diabetes study. His interests include critical appraisal of evidence-based medicine and diabetes commissioning and service development. He has presented to healthcare audiences throughout the UK and beyond.

In 2003, Stephen was instrumental in establishing an intermediate-care GP with a Special Interest in Diabetes clinic in Medway in answer to the burgeoning burden of diabetes referrals to the local Medway Maritime Hospital. He has written articles on the evolving role of community-based diabetes care. He trains healthcare professionals wishing to advance to supplementary or independent prescribing status. In addition, he has served in a joint role of Primary Care Medical Advisor for Diabetes UK and Clinical Diabetes Lead for the Royal College of General Practitioners.

David Millar-Jones (Chair)

GP with a Special Interest in Diabetes, Cwmbran

David Millar-Jones is a GP in Cwmbran and has established a successful intermediate care service within the locality. He is also an Associate Specialist in Diabetes and Lecturer at Cardiff Medical School. This gives him a good working knowledge of secondary care and educational needs and standards. David is also an Executive Committee Member for the Welsh Endocrine Society, whose aim is to direct the Welsh Assembly Government regarding endocrinology in Wales.
 

David stands for good standards of care, structure, education and support within primary care in order for it to be recognised as the principal arena for the management of diabetes. He also believes that there is a great need for increased understanding of secondary care by the primary care community, as to the benefits that can be offered within a community setting. He aims to continue to promote intermediate care services and facilitate structured education.

This virtual broadcast series has been funded by Novo Nordisk. Novo Nordisk has had no editorial input into, or control over,
the content of the webinar. PCDS is responsible for the content of the webinar and the selection of speakers.

Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist?

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional webcast, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim and Lilly Diabetes Alliance products will be discussed in this webcast.

Speakers

Professor Naveed Sattar

Professor of Metabolic Medicine, Institute of Cardiovascular & Medical Sciences, University of Glasgow; Honorary Consultant in Metabolic Medicine, Glasgow Royal Infirmary

Professor Martin Cowie

Professor of Cardiology, Health Services Research, Imperial College, University of London; Honorary Consultant, Royal Brompton and Harefield NHS Trust

What does this programme offer?

Join Professor Martin Cowie and Professor Naveed Sattar as they present a pre-recorded clinical discussion. Sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance.

Excess mortality in type 2 diabetes is largely related to an increased incidence of cardiovascular disease1, yet patient management has traditionally focused on improving glycaemic control – with limited evidence of macrovascular benefit.2

Since the landmark EMPA-REG OUTCOME trial in 20153 cardiovascular outcome trials have begun to provide evidence of cardiovascular benefit with some SGLT2 inhibitors and GLP-1 receptor agonists. This evidence has been reflected in new and updated guidance recommendations, including the 2019 European Society of Cardiology guidelines on diabetes, pre-diabetes and cardiovascular disease4 – in light of this, do cardiologists have an expanded role in treating type 2 diabetes?

The presentations cover topics including:

Putting the evidence into practice: does the cardiologist have an expanded role in the treatment of type 2 diabetes?

Professor Martin Cowie​

For adverse events reporting and prescribing information UKIE

Type 2 diabetes, cardiovascular outcomes and the role of SGLT2 inhibitors

Professor Naveed Sattar

For adverse events reporting and prescribing information UKIE

Jardiance is the most initiated SGLT2i inhibitor in the UK5*

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise6

Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.6

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 3281627 (freephone)

Adverse events should be reported. Reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue 
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 2913960 Fax: +44 1344 742661
or by email: PV_local_UK_Ireland@boehringer-ingelheim.com
*

Defined as new patients prescribed JARDIANCE, patients switched to JARDIANCE from another type 2 diabetes treatment or JARDIANCE added to another type 2 diabetes treatment

References
1. Tancredi M et al. N Engl J Med. 2015;373:1720–1732.
2. Turnbull FM et al. Diabetologia. 2009;52:2288–2298.3. Zinman B et al. N Engl J Med. 2015;373:2117–2128.
4. Cosentino F et al. Eur Heart J 2020;41:255.
5. Data on file. IQVIA new patient opportunity data June 2020. Boehringer Ingelheim.
6. Jardiance Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/28973 (accessed October 2020)

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.